Related Experiment Videos
Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma
Cancer Chemotherapy and Pharmacology
|January 1, 1982
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.
Cancer chemotherapy and pharmacology·2026
Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.
Cancer chemotherapy and pharmacology·2026
Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
Cancer chemotherapy and pharmacology·2026
CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.
Cancer chemotherapy and pharmacology·2026
Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
Cancer chemotherapy and pharmacology·2026
Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer.
Cancer chemotherapy and pharmacology·2026
Oxygen-Gradient-Responsive Photosensitizing Gadolinium Phthalocyaninate for Self-Adaptive Type II/I Photodynamic Therapy Toward Heterogeneous Tumor Suppression.
Small (Weinheim an der Bergstrasse, Germany)·2026
An Immunogenic Cell Death-Enhanced Self-Assembled Nanoparticle-Composite Hydrogel for Postoperative Local Immunotherapy of Melanoma.
Omics : a journal of integrative biology·2026